Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  HIV Infection

  Free Subscription


Articles published in Antimicrob Agents Chemother

Retrieve available abstracts of 59 articles:
HTML format
Text format



Single Articles


    May 2017
  1. STEENS JM, Scherrer D, Gineste P, Barrett PN, et al
    Safety, Pharmacokinetics and_Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment- Naive HIV Infected Subjects: a Phase II Randomized, Controlled Study.
    Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00545.
    PubMed     Text format     Abstract available


  2. GIACOBBI NS, Sluis-Cremer N
    In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine and MIV-150: NNRTI Microbicides in Clinical Development for the Prevention of HIV-1 Infection.
    Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00277.
    PubMed     Text format     Abstract available


  3. PRESSIAT C, Amorissani-Folquet M, Yonaba C, Treluyer JM, et al
    Pharmacokinetics of Efavirenz in 2-3 years old children: a high dose of 25 mg/kg per day.
    Antimicrob Agents Chemother. 2017 May 8. pii: AAC.00297.
    PubMed     Text format     Abstract available


    April 2017
  4. ZHANG Y, Clarke W, Marzinke MA, Piwowar-Manning E, et al
    Evaluation of a multi-drug assay for monitoring adherence to a regimen for HIV pre-exposure prophylaxis in a clinical study (HIV Prevention Trials Network 073).
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.02743.
    PubMed     Text format     Abstract available


  5. NAKAMURA RL, Burlingame MA, Yang S, Crosby DC, et al
    Identification and optimization of thienopyridine carboxamides as inhibitors of HIV regulatory complexes.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.02366.
    PubMed     Text format     Abstract available


  6. ZHAO C, Gunawardana M, Villinger F, Baum MM, et al
    Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.02465.
    PubMed     Text format     Abstract available


  7. DAS K, Martinez SE, Arnold E
    Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex that Confer Multi-Nucleoside Drug Resistance.
    Antimicrob Agents Chemother. 2017 Apr 10. pii: AAC.00224.
    PubMed     Text format     Abstract available


    March 2017
  8. RIMAWI BH, Johnson E, Rajakumar A, Tao S, et al
    Pharmacokinetics and Placental Transfer of Elvitegravir and Dolutegravir, and Other Antiretrovirals during Pregnancy.
    Antimicrob Agents Chemother. 2017 Mar 27. pii: AAC.02213.
    PubMed     Text format     Abstract available


  9. HUBER AD, Michailidis E, Tang J, Puray-Chavez MN, et al
    3-hydroxypyrimidine-2,4-diones as novel hepatitis B virus antivirals targeting the viral ribonuclease H.
    Antimicrob Agents Chemother. 2017 Mar 20. pii: AAC.00245.
    PubMed     Text format     Abstract available


  10. MOYA B, Barcelo IM, Bhagwat S, Patel M, et al
    WCK 5107 (Zidebactam) & WCK 5153: Novel inhibitors of PBP2 showing potent "beta-lactam enhancer" activity against Pseudomonas aeruginosa, including multidrug-resistant metallo-beta-lactamase-producing high-risk clones.
    Antimicrob Agents Chemother. 2017 Mar 13. pii: AAC.02529.
    PubMed     Text format     Abstract available


  11. NIGO M, Diaz L, Carvajal LP, Tran TT, et al
    Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format     Abstract available


    February 2017
  12. VIDYAPRAKASH E, Abrams AJ, Shafer WM, Trees DL, et al
    Whole genome sequencing of a large panel of contemporary Neisseria gonorrhoeae clinical isolates indicates that a wild-type mtrA gene is common: implications for inducible antimicrobial resistance.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.00262.
    PubMed     Text format     Abstract available


  13. KOUTSOUDAKIS G, Paris de Leon A, Herrera C, Dorner M, et al
    Oligonucleotide-lipid conjugates forming G-quadruplex structures are potent and pangenotypic hepatitis C virus entry inhibitors in vitro and ex vivo.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.02354.
    PubMed     Text format     Abstract available


  14. ROBERTS O, Khoo S, Owen A, Siccardi M, et al
    Interaction of Rifampicin and Darunavir/Ritonavir or Darunavir/Cobicistat In Vitro.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.01776.
    PubMed     Text format     Abstract available


  15. CHOI SR, Britigan BE, Narayanasamy P
    Ga(III) Nanoparticles Inhibit Growth of Both TB and HIV and Release of IL-6 and IL-8 in Co-Infected Macrophages.
    Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02505.
    PubMed     Text format     Abstract available


    January 2017
  16. LE VT, Le HN, Pinheiro MG, Hahn KJ, et al
    Effects of tedizolid phosphate on survival outcomes and suppression of production of staphylococcal toxins in a rabbit model of MRSA necrotizing pneumonia.
    Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02734.
    PubMed     Text format     Abstract available


  17. DIEP BA, Hillard JJ, Le VT, Tkaczyk C, et al
    Targeting Alpha Toxin to Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia.
    Antimicrob Agents Chemother. 2017 Jan 23. pii: AAC.02456.
    PubMed     Text format     Abstract available


  18. GOMARASCA M, Martins TF, Greune L, Hardwidge PR, et al
    Bacterial-derived cell-penetrating peptides deliver gentamicin to kill intracellular pathogens.
    Antimicrob Agents Chemother. 2017 Jan 17. pii: AAC.02545.
    PubMed     Text format     Abstract available


    December 2016
  19. GROSSMAN NT, Casadevall A
    Physiological Differences in C. neoformans in vitro versus in vivo and Their Effects on Antifungal Susceptibility.
    Antimicrob Agents Chemother. 2016 Dec 28. pii: AAC.02108.
    PubMed     Text format     Abstract available


  20. ZERBATO JM, Tachedjian G, Sluis-Cremer N
    Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Virus Production from Latently Infected Resting CD4+ T Cells Following Latency Reversal.
    Antimicrob Agents Chemother. 2016 Dec 19. pii: AAC.01736.
    PubMed     Text format     Abstract available


  21. LOMONOSOVA E, Zlotnick A, Tavis JE
    Synergistic Interactions between Hepatitis B Virus Ribonuclease H Antagonists and Other Inhibitors.
    Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.02441.
    PubMed     Text format     Abstract available


  22. FOFANA MO, Shrestha S, Knight GM, Cohen T, et al
    Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model.
    Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.00498.
    PubMed     Text format     Abstract available


  23. VALADE E, Bouazza N, Lui G, Martinez Illamola S, et al
    Population Pharmacokinetic Modeling of Tenofovir in the Male Genital Tract of HIV-infected Patients.
    Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.02062.
    PubMed     Text format     Abstract available


  24. KING JR, Khatri A, Trinh R, Viani RM, et al
    Pharmacokinetic Evaluation of Darunavir Administered Once or Twice daily in Combination with Ritonavir or the Three Direct Acting Antiviral Regimen of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir in Adults Co-infected with Hepatitis C and Human I
    Antimicrob Agents Chemother. 2016 Dec 5. pii: AAC.02135.
    PubMed     Text format     Abstract available


    November 2016
  25. FOISSAC F, Blume J, Treluyer JM, Tylleskar T, et al
    Are Prophylactic and Therapeutic Target Concentrations Different? The Case of Lopinavir/ritonavir or Lamivudine Administered to Infants for the Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.
    Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01869.
    PubMed     Text format     Abstract available


  26. PENROSE KJ, Wallis CL, Brumme CJ, Hamanishi KA, et al
    Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals on Failing First-Line Antiretroviral Therapy in South Africa.
    Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01805.
    PubMed     Text format     Abstract available


  27. KHALILIEH S, Yee KL, Sanchez RI, Triantafyllou I, et al
    Results of a doravirine-atorvastatin drug-drug interaction study.
    Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.01364.
    PubMed     Text format     Abstract available


  28. YEE KL, Sanchez RI, Auger P, Liu R, et al
    An Evaluation of Doravirine Pharmacokinetics When Switching From Efavirenz to Doravirine in Healthy Subjects.
    Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.01757.
    PubMed     Text format     Abstract available


  29. PONCE CA, Chabe M, George C, Cardenas A, et al
    High prevalence of Pneumocystis jirovecii dihydropteroate synthase gene mutations in patients with first episode of Pneumocystis pneumonia in Santiago, Chile, and their clinical response to trimethoprim-sulfamethoxazole therapy.
    Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.01290.
    PubMed     Text format     Abstract available


  30. ANTWI S, Yang H, Enimil A, Sarfo AM, et al
    Pharmacokinetics of the First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection.
    Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.01701.
    PubMed     Text format     Abstract available


  31. MANDAL S, Belshan M, Holec A, Zhou Y, et al
    An enhanced Emtricitabine loaded long-acting nano-formulation for prevention or treatment of HIV infection.
    Antimicrob Agents Chemother. 2016 Nov 7. pii: AAC.01475.
    PubMed     Text format     Abstract available


  32. SONOIKI E, Nsanzabana C, Legac J, Sindhe KM, et al
    Altered Plasmodium falciparum sensitivity to the antiretroviral protease inhibitor lopinavir associated with polymorphisms in pfmdr1.
    Antimicrob Agents Chemother. 2016 Nov 7. pii: AAC.01949.
    PubMed     Text format     Abstract available


    October 2016
  33. BAM RA, Hansen D, Irrinki A, Mulato A, et al
    TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells.
    Antimicrob Agents Chemother. 2016 Oct 31. pii: AAC.01369.
    PubMed     Text format     Abstract available


  34. AOURI M, Barcelo C, Guidi M, Rotger M, et al
    Population pharmacokinetics and pharmacogenetics analysis of Rilpivirine in HIV-1 infected individuals.
    Antimicrob Agents Chemother. 2016 Oct 31. pii: AAC.00899.
    PubMed     Text format     Abstract available


  35. ROBARGE JD, Metzger IF, Lu J, Thong N, et al
    Population pharmacokinetic modeling to estimate the contribution of genetic and non-genetic factors of efavirenz disposition.
    Antimicrob Agents Chemother. 2016 Oct 31. pii: AAC.01813.
    PubMed     Text format     Abstract available


  36. SCHERRER D, Rouzier R, Cardona M, Barrett PN, et al
    Food effect on pharmacokinetic parameters of ABX464 administered orally: a randomized trial in healthy male subjects.
    Antimicrob Agents Chemother. 2016 Oct 31. pii: AAC.01288.
    PubMed     Text format     Abstract available


    September 2016
  37. TSIANG M, Jones GS, Goldsmith J, Mulato A, et al
    Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Antimicrob Agents Chemother. 2016 Sep 19. pii: AAC.01474.
    PubMed     Text format     Abstract available


  38. FENAUX M, Lin X, Yokokawa F, Sweeney Z, et al
    Anti-viral nucleotide incorporation by recombinant human mitochondrial RNA polymerase is predictive for increased in vivo mitochondrial toxicity risk.
    Antimicrob Agents Chemother. 2016 Sep 19. pii: AAC.01253.
    PubMed     Text format     Abstract available


  39. AMANO M, Salcedo-Gomez PM, Zhao R, Yedidi RS, et al
    A Modified P1 Moiety Enhances in vitro Antiviral Activity against Various Multi-Drug-Resistant HIV-1 Variants and in vitro CNS Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
    Antimicrob Agents Chemother. 2016 Sep 12. pii: AAC.01428.
    PubMed     Text format     Abstract available


  40. DESTA Z, Metzger IF, Thong N, Lu JB, et al
    Inhibition of CYP2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.
    Antimicrob Agents Chemother. 2016 Sep 6. pii: AAC.01000.
    PubMed     Text format     Abstract available


    August 2016
  41. CASTILLO-MANCILLA J, Seifert S, Campbell K, Coleman S, et al
    Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
    Antimicrob Agents Chemother. 2016 Aug 29. pii: AAC.01017.
    PubMed     Text format     Abstract available


  42. GROOMS TN, Vuong HR, Tyo KM, Malik DA, et al
    Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold to Prevent HIV Infection.
    Antimicrob Agents Chemother. 2016 Aug 22. pii: AAC.00956.
    PubMed     Text format     Abstract available


  43. DIEP BA, Le VT, Visram ZC, Rouha H, et al
    Improved protection in a rabbit model of CA-MRSA necrotizing pneumonia upon neutralization of leukocidins in addition to alpha-hemolysin.
    Antimicrob Agents Chemother. 2016 Aug 15. pii: AAC.01213.
    PubMed     Text format     Abstract available


  44. KHATRI A, Trinh R, Zhao W, Podsadecki T, et al
    Drug-Drug Interaction Between the Direct-acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir and the HIV Antiretroviral Agents Dolutegravir or Abacavir Plus Lamivudine.
    Antimicrob Agents Chemother. 2016 Aug 8. pii: AAC.00795.
    PubMed     Text format     Abstract available


  45. ROCKWOOD NN, Meintjes G, Chirehwa M, Wiesner L, et al
    HIV-1 co-infection does not reduce exposure to rifampicin, isoniazid, and pyrazinamide in South African tuberculosis outpatients.
    Antimicrob Agents Chemother. 2016 Aug 1. pii: AAC.00480.
    PubMed     Text format     Abstract available


  46. GONZALEZ-SERNA A, Genebat M, De Luna-Romero M, Tarancon-Diez L, et al
    Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-term Maraviroc Monotherapy Exposure.
    Antimicrob Agents Chemother. 2016 Aug 1. pii: AAC.01326.
    PubMed     Text format     Abstract available


    July 2016
  47. MARTINEZ ZS, Castro E, Seong CS, Ceron MR, et al
    Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity.
    Antimicrob Agents Chemother. 2016 Jul 18. pii: AAC.00341.
    PubMed     Text format     Abstract available


  48. LE VT, Tkaczyk C, Chau S, Rao RL, et al
    Acute bacterial skin and skin structure infection: Critical role of alpha-toxin and protective effects of its neutralization by a human antibody.
    Antimicrob Agents Chemother. 2016 Jul 11. pii: AAC.00710.
    PubMed     Text format     Abstract available


  49. CECKOVA M, Reznicek J, Ptackova Z, Cerveny L, et al
    Interaction of lamivudine with ABC and SLC transporters: role in placental transport.
    Antimicrob Agents Chemother. 2016 Jul 11. pii: AAC.00648.
    PubMed     Text format     Abstract available


  50. NOGUCHI LM, Montgomery ET, Biggio JR, Hendrix CW, et al
    Detectable tenofovir levels in breastfeeding infants of mothers exposed to topical tenofovir.
    Antimicrob Agents Chemother. 2016 Jul 11. pii: AAC.00645.
    PubMed     Text format     Abstract available


  51. LI M, Mislak AC, Foli Y, Agbosu E, et al
    DNA Polymerase-gamma R953C Mutant is Associated with ART-Induced Mitochondrial Toxicity.
    Antimicrob Agents Chemother. 2016 Jul 5. pii: AAC.00976.
    PubMed     Text format     Abstract available


  52. VILLEGAS G, Calenda G, Zhang S, Mizenina O, et al
    In vitro exposure to PC-1005 and cervicovaginal lavages from women vaginally administered PC-1005 inhibit HIV-1 and HSV-2 infection in human cervical mucosa.
    Antimicrob Agents Chemother. 2016 Jul 5. pii: AAC.00392.
    PubMed     Text format     Abstract available


    June 2016
  53. LU Y, Goti V, Chaturvedula A, Haberer JE, et al
    Population pharmacokinetics of tenofovir in HIV-1 uninfected members of sero-discordant couples and effect of dose reporting methods.
    Antimicrob Agents Chemother. 2016 Jun 27. pii: AAC.00559.
    PubMed     Text format     Abstract available


  54. CHEN X, Castillo-Mancilla JR, Seifert SM, McAllister K, et al
    Analysis of the endogenous deoxynucleoside triphosphate pool in HIV positive and negative individuals receiving tenofovir-emtricitabine.
    Antimicrob Agents Chemother. 2016 Jun 27. pii: AAC.01019.
    PubMed     Text format     Abstract available


    May 2016
  55. RIVERO-BUCETA E, Sun L, Gualda BM, Doyaguez EG, et al
    An unexpected twist: optimization of a class of tryptophan dendrimers that inhibit HIV replication leads to a selective, specific and low nanomolar inhibitor of clinical isolates of enterovirus A71.
    Antimicrob Agents Chemother. 2016 May 31. pii: AAC.00626.
    PubMed     Text format     Abstract available


  56. CUSTODIO JM, Fordyce M, Garner W, Vimal M, et al
    Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-uninfected Subjects with Severe Renal Impairment.
    Antimicrob Agents Chemother. 2016 May 23. pii: AAC.00005.
    PubMed     Text format     Abstract available


  57. VARGAS G, Vincent KL, Zhu Y, Szafron D, et al
    In vivo rectal mucosal barrier function imaging in a large animal model using confocal endomicroscopy: implications for injury assessment and use in HIV prevention studies.
    Antimicrob Agents Chemother. 2016 May 16. pii: AAC.00134.
    PubMed     Text format     Abstract available


  58. CHUNG DH, Golden JE, Adcock RS, Schroeder CE, et al
    Discovery of a broad-spectrum antiviral compound that inhibits pyrimidine biosynthesis and establishes a type 1 interferon-independent antiviral state.
    Antimicrob Agents Chemother. 2016 May 16. pii: AAC.00282.
    PubMed     Text format     Abstract available


  59. WARRILOW AG, Parker JE, Price CL, Nes WD, et al
    The Investigational Drug VT-1129 is a Highly Potent Inhibitor of Cryptococcus species CYP51 but only Weakly Inhibits the Human Enzyme.
    Antimicrob Agents Chemother. 2016 May 9. pii: AAC.00349.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: